Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suramin in Refractory/Relapsed Multiple Myeloma and Castleman's Disease
NCT00002652Phase 2Completed
- Sponsor
- University of Arkansas
- Start
- May 1995
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of suramin in multiple myeloma (MM) and Castleman disease (CD), sponsored by University of Arkansas. Primary endpoint: Tumor Response. Started May 1995; status: completed.
02
Drugs
suramin
03
Conditions
multiple myeloma (MM)Castleman disease (CD)
Beyond the preview
Go deeper on NCT00002652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002652.